Market capitalisation is the post-issue share count in the offer document’s capital structure (54,85,056 shares) multiplied by the upper end of the price band, ₹208. It is arithmetic on those two filed figures, not a valuation.
| ₹ crore | 2024 | 2025 |
|---|---|---|
| Revenue | ₹23.96 | ₹45.24 |
| Expenses | — | — |
| Net profit (PAT) | ₹2.15 | ₹7.29 |
| PAT margin | 9.0% | 16.1% |
| Total assets | ₹34.65 | ₹56.52 |
The founding owners and their group entities.
Post-issue pattern as filed with the NSE. Pre-issue register from the RHP capital structure, cross-checked against exchange data. Pre-issue percentages are taken from the disclosure, never estimated.
| Application | Shares | Amount at ₹208 |
|---|---|---|
| Individual investor (min)minimum application | 1,200 | ₹2,49,600 |
The minimum application is 1,200 shares, ₹2,49,600 at the ₹208 cut-off. Since 1 July 2025 SME issues take a minimum application of ₹2,00,000 or more from individual investors; the HNI minimum is set in the RHP. Amounts are shown at the upper band because applications are made at the cut-off price.
Strengths and risk factors from this issue’s prospectus aren’t available yet.
Allotment is decided and published by the issue’s registrar, not by the exchange and not by alphave. For Avience Biomedicals Limited, the registrar is Skyline Financial Services Pvt. Ltd. — allotment is finalised in the days between the issue closing on 22 Jun 2026 and listing on 25 Jun 2026.
Allotment and refund dates follow SEBI’s T+3 listing timeline in trading days and are tentative until the registrar and the exchange confirm them. alphave does not hold allotment results — only the registrar can show whether an application was allotted.
The registrar publishes allotment on its own portal: Skyline. Your bank will also show the blocked amount released if shares were not allotted.
The Avience Biomedicals Limited IPO price band is ₹208 to ₹208 per share. Applications are made at the cut-off price, which is the upper end of the band.
One lot is 1200 shares, so a single application at the ₹208 cut-off costs ₹2,49,600. One lot already exceeds the ₹2,00,000 retail limit, so this issue can only be applied for in the HNI category.
₹2,49,600 — one lot of 1200 shares at ₹208. Bids in the non-institutional category start above ₹2,00,000 and are made in multiples of the lot.
Avience Biomedicals Limited is an SME issue listing on NSE SME. SME issues have a larger minimum lot and trade on the exchange's SME platform after listing. The lead manager is Fintellectual Corporate Advisors Pvt. Ltd.
The issue size is ₹30.24 crore, of which ₹30.24 crore is a fresh issue.
The registrar processes the allotment and the refunds. Contact details are as printed in the offer document; the exchange and your broker cannot change an allotment.
Grey Market Premium is the price at which an unlisted IPO application or share changes hands informally, before the stock is listed on the exchange. It is quoted as a rupee figure over the issue price: a premium of ₹40 on a ₹208 upper band means the grey market is dealing at issue price plus that premium.
The grey market is an over-the-counter market between private dealers. It is not operated or supervised by NSE, BSE or SEBI, no trade is settled through a clearing corporation, and no dealer is obliged to publish or honour a quote. Figures are collected by third-party reporters and different sources routinely disagree, which is why a premium can move sharply within a day or vanish entirely once bidding closes.
Grey Market Premium is an unofficial, unregulated over-the-counter datapoint reported by third parties. It is not a price, a forecast, or an indication of listing gains, and is not investment advice.